Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis by Henry L. Y. Chan et al.
ORIGINAL RESEARCH
Renal Function in Nucleos(t)ide Analog-Treated
Patients With Chronic Hepatitis B: A Systematic
Literature Review and Network Meta-Analysis
Henry L. Y. Chan . Javed Shaikh . Subhajit Gupta . Kamal Hamed
Received: March 15, 2016 / Published online: May 4, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Renal safety is an important
factor in selecting the most appropriate
nucleos(t)ide analog (NA) treatment for
patients with chronic hepatitis B (CHB). This
systematic literature review and network
meta-analysis aimed to assess renal function
associated with telbivudine treatment
compared to other NAs in patients with CHB.
Methods: A systematic literature search via
Medline, Medline In-Process, Embase, and the
Cochrane library for publications of
randomized controlled trials and observational
studies was conducted. Network meta-analysis
was performed to compare renal function with
telbivudine treatment versus other NAs after
1 year of therapy.
Results: Overall, 40 (six randomized controlled
and 34 observational) studies were included for
review. Telbivudine consistently showed an
improvement in renal function as measured by
an estimated glomerular filtration rate (eGFR)
over various time points regardless of the method
of measurement. Changes in eGFR (mL/min)
from baseline and corresponding 95% credible
intervals with various NAs were as follows:
monotherapies (telbivudine: 7.78 [6.91, 8.65],
entecavir: -1.07 [-4.80, 2.62], lamivudine:
-6.08 [-13.35, 1.15], tenofovir: -9.53 [-14.31,
-4.89]) and combination therapies
(telbivudine? adefovir: 8.37 [-34.00, 50.34],
telbivudine? tenofovir: 8.29 [-0.05, 16.64],
entecavir? adefovir: 4.15 [-38.55, 46.37],
telbivudine? lamivudine: 0.51 [-11.77, 12.96],
and lamivudine? adefovir: -0.39 [-42.48,
41.21]). At 1 year, the change in eGFR from
baseline was significantly higher with telbivudine
compared to other NAs.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a major
global public health concern. Evidence from
available data suggest that an estimated
240 million individuals are chronically infected
with HBV worldwide, and approximately
one million die from chronic hepatitis B
(CHB)-related diseases every year [1, 2].
Previous studies have described an association
between CHB and chronic kidney disease (CKD)
[3–6]. Nearly 15–30% of patients with CHB have
baseline renal dysfunction or comorbidities
associated with CKD, such as diabetes and
hypertension. Findings from previous studies
have implicated glomerular diseases such as
membranous nephropathy and
mesangiocapillary glomerulonephritis as the
underlying causes of renal dysfunction caused
by HBV [7, 8]. Renal dysfunction, marked by a
decrease in estimated glomerular filtration rate
(eGFR), is frequently observed in patients with
compensated CHB. Nucleos(t)ide analogs (NAs),
the mainstay of CHB therapy, are primarily
eliminated unchanged through renal route [9].
Adefovir and tenofovir have been associated
with nephrotoxicity related to the
accumulation of nucleotide metabolites in
renal tubular cells [10]. An observational cohort
study conducted in patients with CHB from two
German centers concluded that treatment of
HBV monoinfection with adefovir (n = 32),
entecavir (n = 32), lamivudine (n = 36), or
tenofovir (n = 37) resulted in a mild decrease in
renal function [11–13]. Therefore, renal safety is
an important factor in selecting the most
appropriate NA treatment for patients with
CHB, particularly in those who are at risk for
renal impairment. Recent literature suggests that
telbivudine is associated with improvement in
renal function in patients with CHB. However,
there is a lack of systematic evidence base
regarding the comparison of renal function
associated with NAs. Hence, it is important to
collate all available evidence and summarize the
data regarding the effect of various NAs on renal
function in patients with CHB, either as
monotherapy or combination therapy. The aim
of the current systematic literature review (SLR)
and a network meta-analysis (NMA) is to assess
renal function associated with telbivudine
treatment compared to other NAs in patients
with CHB.
METHODS
This SLR followed a standard, systematic review
methodology endorsed by the Cochrane
Collaboration [14] and the National Institute
for Health and Care Excellence (NICE) in the UK
[15]. The SLR was conducted and reported in
accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [16].
Inclusion and Exclusion Criteria
Inclusion Criteria
All randomized controlled trials (RCTs) and
observational studies published in the English
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language, conducted in patients with CHB
regardless of their hepatitis B envelope antigen
(HBeAg) status, were included. Studies
evaluating interventions/comparators (either
monotherapy or combination therapies) such
as adefovir, entecavir, lamivudine, telbivudine,
tenofovir, and placebo with reported eGFR
outcomes (either absolute change or
percentage improvement from baseline) were
included.
Exclusion Criteria
Animal and in vitro studies; studies in patients
co-infected with human immunodeficiency
virus, hepatitis C virus, or hepatitis D virus;
and studies that did not report interventions,
comparators, and outcomes of interest were
excluded. In addition, review articles, editorials,
case reports, case series, and economic
evaluations were excluded.
Search Strategy
Comprehensive literature searches were
conducted by searching electronic databases
(Medline, Medline In-Process, Embase, and
the Cochrane Library) from the inception of
each database to July 2015. The multistring
search strategy was based on a combination
of medical subject headings (MeSH) and
keywords including ‘‘adefovir’’, ‘‘entecavir’’,
‘‘lamivudine’’, ‘‘telbivudine’’, ‘‘tenofovir’’,
‘‘chronic hepatitis B’’, ‘‘hepatitis B’’, ‘‘chronic
kidney disease’’, ‘‘CKD’’, ‘‘glomerular filtration
rate’’, and ‘‘eGFR’’. Reference lists of any
relevant studies, recent systematic reviews,
or meta-analyses were also searched for any
additional studies to add to the evidence
base.
First-Level Screening of Citations
All the publications retrieved from the literature
search were screened based on the title and
abstract provided with each citation. The
inclusion/exclusion criteria were uniformly
applied across all the publications. Two
independent reviewers screened the retrieved
abstracts, and a third independent reviewer
reconciled any discrepancies between them.
Publications that did not meet the eligibility
criteria were excluded, and the reasons for
exclusion were documented. Subsequently,
full-text copies of all the publications that met
the eligibility criteria were downloaded.
Second-Level Screening of Citations
The inclusion and exclusion criteria were
uniformly applied across all the full-text
publications. The same two reviewers screened
all the manuscripts, and the third independent
reviewer reconciled any discrepancies between
them. Publications that did not meet the
eligibility criteria were excluded, and the
reasons for exclusion were documented.
Publications that met the eligibility criteria
were subjected to data extraction.
Data Extraction
The same reviewers extracted data
independently using a prespecified data
extraction template, and as before, the third
independent reviewer resolved any
discrepancies. Data were extracted from
various information sources in a study, such as
objectives, methods, inclusion and exclusion
criteria, baseline demographic and clinical
characteristics, interventions, efficacy
864 Adv Ther (2016) 33:862–875
outcomes, and conclusions. Studies with
multiple publications were linked to one
another and extracted as a single study.
Critical Appraisal (Quality Assessment)
Each included study was assessed for
methodological quality (internal and external
validity). RCTs that met the eligibility criteria
for review were critically appraised for quality
based on the NICE recommendations [15]. All
included observational studies were critically
appraised for quality based on the Downs and
Black checklist [17].
Assessment of Endpoints
The primary endpoint of the analysis was change
in eGFR from baseline. Most of the studies
reported the renal function outcomes at
48–52 weeks. There were few studies reporting
renal function outcomes at 2-year follow-up.
Hence, the study endpoints were analyzed at a
time point of 1 year (48–52 weeks). For studies
that did not report change in eGFR from
baseline, the change was calculated based on
the reported baseline and endpoint eGFR values.
Network Meta-Analysis
The NMA was performed using statistical
methods to combine data from various studies
in order to obtain a coherent picture of
treatment outcomes and compare various
treatment options. The statistical models for
conducting NMA relate the underlying
outcomes to the effects of treatment and any
other factors (covariates). The models used to
conduct this NMA were derived from the Report
of the International Society for
Pharmacoeconomics and Outcomes Research
(ISPOR) Task Force on Indirect Treatment
Comparisons Good Research Practices: Part 2
[18] and the NICE Technical Support Document
2 (TSD2) [19]. For the purpose of the present
analysis, Bayesian models were used.
Furthermore, in order to assess the
inconsistencies in the evidence networks, we
compared a standard network consistency model
with an ‘‘inconsistency’’ or unrelated mean
effects model. According to the NICE Decision
Support Unit (DSU) guidelines, this
methodology is more efficient compared to
existing methodologies to detect
inconsistencies [20]. The statistical software R
(version 3.2.2, R Foundation for Statistical
Computing, Vienna, Austria) was used for
analysis. An integrated graphical user interface
(GUI) for R, Rstudio (version 0.98.945), was used
to run all the R scripts. The package R2WinBUGS
was used to retrieve WinBUGS 1.4 from R in
order to run the Bayesian Markov Chain Monte
Carlo (MCMC) algorithm. A feasibility check was
performed to conduct the NMA, and only
non-RCTs were found to be eligible. All
non-RCTs were assumed comparable in terms
of study design, and for studies with missing
standard error (SE) values, SE was assumed to be
10% of the mean change in eGFR from baseline.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




The results of the literature search are
summarized in Fig. 1. The search of the
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literature databases yielded 974 publications. Of
these, 247 were duplicates due to an overlap of
records across the searched databases. Following
the initial screening of these citations, 110
potentially relevant publications were
identified and 49 of them were included after
a more detailed evaluation. Three publications
were additionally identified through a
bibliographic search of the relevant systematic
reviews, yielding 40 studies from 52
publications for synthesis of evidence.
Study Characteristics
Of the 40 studies included, 20 were full-text
publications and 20 were conference abstracts.
In total, six RCTs and 34 observational studies
were included (17 retrospective studies, 12
prospective studies, three non-RCTs, and one
case–control study and cross-sectional study
each). Of the 40 included studies, 35 had an
active control group, and in the remaining five
studies, NAs were compared with untreated
Fig. 1 Flow diagram of the literature search
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controls. Entecavir, telbivudine, and tenofovir
were the most commonly reported treatments.
Thirteen of the 40 studies were multicenter
studies, whereas 16 studies had been conducted
at a single center. In the remaining 11 studies,
the study location was unclear. Overall, 90%
(36/40) of the studies were conducted in
populations with mixed HBeAg status, whereas
only three studies [21–23] enrolled
HBeAg-negative patients and one study [24]
enrolled HBeAg-positive patients. The mean age
among the included studies ranged from 34 [25]
to 55 [26] years. Approximately 15% (6/40) of
the included studies enrolled over 70% of the
male population. Modification of Diet in Renal
Disease (MDRD) was the most commonly used
equation to measure eGFR among the included
studies (see Table S1 in the online
supplementary material).
Critical Appraisal (Quality Assessment)
Of the six RCTs that exhibited similarities
among treatment groups in terms of baseline
characteristics, two studies reported an
adequate method of allocation concealment
and two reported an adequate method of
blinding for patients and caregivers. An
adequate method of statistical analysis was
reported in three studies. For the observational
studies, the majority of relevant information
was missing from the conference abstracts; the
Downs and Black total scores ranged from 2 [27]
to 18 [28]. Overall, the methodological quality
of the included studies was adequate.
Trends for Changes in eGFR over Different
Time Points
Figure 2 shows the changes in eGFR over
different time points across the included
studies for entecavir, lamivudine, telbivudine,
and tenofovir. The plots clearly indicate that
telbivudine consistently showed an increase in
eGFR over different time points regardless of the
method used to measure eGFR. Four studies
reported eGFR with lamivudine at different
time points. A retrospective study comparing
long-term renal function with different NAs
[29] reported eGFR in 77 lamivudine-treated
patients according to the MDRD method. The
baseline eGFR was 86.58 mL/min/1.73 m2, and
the mean [standard deviation (SD)] change
from baseline at 52 weeks was -3.55 (19.13).
In an RCT comparing the safety and efficacy of
telbivudine and lamivudine, patients who
received lamivudine showed a steady decline
in renal function, as evidenced by the evolution
of serum creatinine and eGFR [estimated using
the MDRD and Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI)
methods] [30]. Ten studies reported eGFR with
telbivudine treatment at different time points.
According to these studies, telbivudine
improved renal function. A study by Gane
et al. [31] reported eGFRs calculated using the
MDRD, CKD-EPI, and Cockcroft–Gault (CG)
methods, and indicated improved renal
function in telbivudine-treated patients from
the 2-year GLOBE study. Based on the MDRD
equation, the mean eGFR had increased by
8.5% in telbivudine-treated patients. Improved
renal function was maintained for 4–6 years. In
addition, increased eGFR with telbivudine
treatment was observed in patients at an
increased risk for renal impairment: patients
with a baseline eGFR of 60–89 mL/min/1.73 m2
(?17.2%), those aged[50 years (?11.4%), and
those with liver fibrosis/cirrhosis (?7.2% for
patients with Ishak fibrosis score of 5–6). In
decompensated patients with a high renal risk,
eGFR improved with telbivudine (?2%). In
total, eight studies had reported eGFR with
entecavir at different time points. A study [26]
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conducted in entecavir-treated patients
reported a mean decline in eGFR by 4.1% at
month 18 compared with baseline.
In a retrospective study [38] conducted in
patients with baseline stage II CKD (eGFR,
60–90 mL/min/1.73 m2), entecavir showed
improvements in renal function from 75.8 to
82.5 mL/min/1.73 m2. Only a few studies had
reported eGFR with adefovir at different time
points; hence, a trend diagram could not be
constructed. However, eGFR decreased
persistently with adefovir treatment. The
annual eGFR decline from baseline was
5.62 mL/min (first year), 11.26 mL/min
(second year; P = 0.0008 vs. baseline), and
13.72 mL/min (third year; P = 0.0005 vs.
baseline) [40].
Figure 3 and Table S2 in the online
supplementary material display the trends in
eGFR changes from baseline at 1 year for
different NAs. Both clearly show an increase in
eGFR from baseline with telbivudine treatment,
alone with in combination with other NAs, across
all the included studies with varying sample sizes.
Fig. 2 Trends for eGFR changes over different time points. eGFR estimated glomerular ﬁltration rate
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Hurdles and Assumptions for NMA
A feasibility check was performed to ascertain
the possibility of conducting an NMA with
available data. The included studies were widely
heterogeneous, and considering specific
assumptions, an NMA was possible only in the
non-RCTs. For eGFR changes from baseline at
1 year in the non-RCTs, it was possible to
construct a network diagram for available
evidence. The assumptions used to attempt
the NMA were as follows: all non-RCTs were
comparable in terms of baseline characteristics
and missing SE was computed to be 10% of the
mean change in eGFR from baseline. For the
purpose of analysis, the eGFR values from
different equations were analyzed together.
eGFR Changes from Baseline at 1 Year
(NMA Results)
The network diagram (Fig. 4) shows the full
network of evidence of treatment regimens for
changes in eGFR from baseline at the 1-year time
point.Overall, NMAwas feasible for 12 non-RCTs.
Figure 5 shows the NMA results for NAs.
Changes in eGFR (mL/min) from baseline and
corresponding 95% credible intervals for
different NAs were as follows: monotherapies
(telbivudine: 7.78 [6.91, 8.65], entecavir: -1.07
[-4.80, 2.62], lamivudine: -6.08 [-13.35, 1.15],
and tenofovir: -9.53 [-14.31, -4.89]) and
combination therapies (telbivudine ? adefovir:
8.37 [-34.00, 50.34], telbivudine ? tenofovir:
8.29 [-0.05, 16.64], entecavir ? adefovir: 4.15
[-38.55, 46.37], telbivudine ? lamivudine: 0.51
[-11.77, 12.96], and lamivudine ? adefovir:
-0.39 [-42.48, 41.21]). Therefore, results from
the current NMA strongly suggested that
telbivudine, either as monotherapy or in
combination with other NAs, showed
improvements in positive values for eGFR
change from baseline. The other NAs
consistently resulted in negative values for
eGFR change from baseline.
DISCUSSION
The present study assessed renal function
associated with telbivudine treatment
compared to other NAs in patients with CHB.
Telbivudine consistently showed an increase in
eGFR across various time points, regardless of
the method used to measure eGFR. The NMA
results for changes in eGFR from baseline at
1 year suggested that compared with other
NAs, telbivudine was associated with an
increase in eGFR across all included studies
with varying sample sizes. Initially, the study
intended to analyze changes in eGFR from
baseline at a 2-year time point. However,
considering the limited number of studies
reporting data at 2 years, construction of a
network diagram for NMA was not feasible.
Over the years, published literature has
provided increasing evidence for the
Fig. 3 Trends for eGFR changes from baseline at 1 year.
The size of the bubble corresponds to the sample size for
corresponding treatment. eGFR estimated glomerular
ﬁltration rate
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renoprotective effects of telbivudine [26, 30,
31, 38, 40]. The mechanism of eGFR
improvement with telbivudine remains to be
determined. Numerous studies have shown
that the decline in eGFR associated with
adefovir or tenofovir treatment is attributed
to the activity of these drugs against human
mitochondrial DNA (mtDNA) [34]. The
proximal tubules are intrinsically susceptible
to mitochondrial dysfunction because of
limited anaerobic adenosine triphosphate
(ATP)-generating capacity [41]. These NAs
(adefovir and tenofovir) are primarily excreted
in unchanged forms through urine; therefore,
inhibition of renal c-mtDNA may affect renal
function [42].
A head-to-head cohort study compared the
effects of various NAs on eGFR in Chinese
patients with CHB [40]. The authors concluded
that prolonged telbivudine therapy resulted in
improvements in eGFR, whereas adefovir
therapy was associated with a decrease in
eGFR; moreover, lamivudine and entecavir did
not significantly affect eGFR [40]. The European
Association for the Study of the Liver (EASL)
guidelines recommend that for patients at low
Fig. 4 eGFR changes from baseline at 1 year: network
diagram. This network diagram provides a graphical
summary of direct and indirect evidence available from
trials. A node represents each treatment option. Lines
connecting two nodes represent the direct evidence
comparing the treatments. The numbers between the lines
represent the number of studies available for that particular
treatment comparison. eGFR estimated glomerular
ﬁltration rate
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renal risk receiving long-term NA therapy, renal
function should be monitored every 3 months
during the first year and every 6 months
thereafter if there is no worsening. For patients
at a high renal risk, renal function should be
monitored every month for the first 3 months,
every 3 months until the end of the first year,
and every 6 months thereafter if there is no
worsening [43]. Gane et al. [31] have reported
the renoprotective effects of telbivudine in a
comprehensive analysis of renal function by
using a telbivudine clinical trial database. This
study evaluated renal function, focusing on the
2-year data from the GLOBE study. The authors
showed that renal function, as assessed by the
three equations for eGFR (CG, MDRD, and
CKD-EPI), improved in patients who received
telbivudine, whereas those who received
lamivudine experienced a decline in renal
function. Furthermore, an extension study of
the GLOBE trial showed that even patients
previously treated with lamivudine benefited
from the renoprotective effects of telbivudine,
with an additional increase in their eGFR of
approximately 10%. This study also reported
that eGFR improvement was maintained during
long-term (4–6 years) telbivudine treatment
[31]. An open-label, 2-year extension study
that assessed the safety and efficacy of
long-term telbivudine treatment in 596
patients with CHB without genotypic
resistance after 2 years of initial telbivudine
treatment reported that telbivudine-treated
patients showed a steady increase in eGFR over
2 years, which remained elevated for up to
4 years [44].
Only one meta-analysis has been published
in the literature that evaluated the renal safety
Fig. 5 eGFR changes (95% credible intervals) from baseline at 1 year: network meta-analysis results. eGFR estimated
glomerular ﬁltration rate
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profile of adefovir in patients with CHB [45].
The authors concluded that based on currently
available evidence, adefovir treatment is
associated with an increased risk of renal
dysfunction. However, this study was not an
NMA, and it analyzed RCTs and single-arm
studies differently and used composite
outcomes to define renal dysfunction.
This SLR and NMA have both limitations and
strengths. The main limitations of the NMA are
the non-randomized designs and heterogeneity
among the included studies. The NMA was
feasible under the aforementioned
assumptions, and the network diagram could
be constructed with 12 non-RCTs. The NMA
was not feasible with RCTs, because of the
limited number of these studies. Another
limitation is that half of the studies were
conference abstracts. A sensitivity analysis was
attempted by including only full-text
publications (i.e., excluding conference
abstracts). However, a network diagram for
this sensitivity analysis was not feasible,
because of the limited number of studies and
available data. Similarly, separate analyses for
patients with compensated versus
decompensated cirrhosis, HBeAg-positive
versus HBeAg-negative status, high versus low
baseline HBV DNA level, and eGFR decline
C20% versus \20% were not possible.
Moreover, eGFR values obtained by using
different equations were analyzed together as
there was not enough studies reporting use of
every eGFR equation (MDRD was the most
commonly used equation). The strengths of
SLR and NMA techniques include the
robustness of the methodology based on the
methods and recommendations from the
Cochrane handbook [14], and the NICE
guidelines [15]. A well-defined protocol
including comprehensive search strategy,
eligibility criteria, and data points to be
extracted was followed throughout the
process. The analyses were performed using
the Bayesian MCMC algorithm. Although the
NMA was feasible only with non-RCTs, the data
from RCTs consistently indicated that
telbivudine was associated with improvement
in renal function (see Table S3 in the online
supplementary material).
Thus, results from both clinical trials and
real-world studies strongly suggest that
telbivudine is associated with improvements
in renal function in patients with CHB, either
alone or in combination with other NAs, and
these improvements were observed in patients
with both compensated liver disease as well as
decompensated cirrhosis. Further, the
improvements in renal function were
maintained for up to 6 years. Moreover,
patients with mild renal impairment at
baseline who were treated with telbivudine
also experienced a consistent improvement in
eGFR. Over the years, renal safety has emerged
as an important treatment-related concern in
NA-treated patients. Although viral resistance
and adverse events due to NA treatment are key
factors when selecting a particular therapy for
CHB, the current findings suggest that
telbivudine offers a more favorable renal safety
profile compared to other NAs, which may
make it the drug of choice for patients at risk
for renal dysfunction.
CONCLUSION
This SLR and NMA provide evidence that
telbivudine is associated with a significant
improvement in renal function (eGFR) in
patients with CHB, either alone or in
combination with other NAs.
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